Kamada Ltd. (KMDA), a biopharmaceutical company, Wednesday said it continues to expect full-year revenue in the range of $158 million to $162 million.
Adjusted EBITDA, or adjusted earnings before interest, taxes, depreciation, and amortization for the year is still expected between $32 million and $35 million.
For fiscal 2025, the company sees revenue in the range of $178 million - $182 million and adjusted EBITDA of $38 million - $42 million.
The mid-point of the 2025 outlook represents an increase of 13 percent in revenues and 19 percent in adjusted EBITDA based on the mid-point of the 2024 guidance.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.